BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17884200)

  • 1. Both levosimendan and dobutamine treatments result in significant reduction of NT-proBNP levels, but levosimendan has better and prolonged neurohormonal effects than dobutamine.
    Cavusoglu Y; Tek M; Birdane A; Ata N; Demirustu C; Gorenek B; Unalir A; Timuralp B
    Int J Cardiol; 2008 Jul; 127(3):e188-91. PubMed ID: 17884200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the clinical, hemodynamic and neurohormonal response to levosimendan administration in decompensated heart failure patients. One-month follow-up.
    Sargento L; Brito D; Matias JS; Madeira H
    Rev Port Cardiol; 2007; 26(7-8):717-26. PubMed ID: 17939581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients.
    Kyrzopoulos S; Adamopoulos S; Parissis JT; Rassias J; Kostakis G; Iliodromitis E; Degiannis D; Kremastinos DT
    Int J Cardiol; 2005 Mar; 99(3):409-13. PubMed ID: 15771921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
    Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
    Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
    Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role for precursor Pro-B type natriuretic peptide in assessing response to therapy and prognosis in patients with decompensated heart failure treated with nesiritide.
    Miller WL; Burnett JC; Hartman KA; Hodge DO; Giuliani I; Minard F; Larue C; Jaffe AS
    Clin Chim Acta; 2009 Aug; 406(1-2):119-23. PubMed ID: 19523938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and prognostic value of N-terminal pro B-type natriuretic peptide (NT-proBNP) in patients with chronic aortic regurgitation.
    Weber M; Hausen M; Arnold R; Moellmann H; Nef H; Elsaesser A; Mitrovic V; Hamm C
    Int J Cardiol; 2008 Jul; 127(3):321-7. PubMed ID: 18055041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness and predictive value of circulating NT-proBNP levels to stratify patients for referral and priority treatment in a specialized outpatient heart failure center.
    Amir O; Paz H; Ammar R; Yaniv N; Schliamser JE; Lewis BS
    Isr Med Assoc J; 2008 Feb; 10(2):109-12. PubMed ID: 18432021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic improvement of acutely decompensated heart failure patients is associated with decreasing levels of NT-proBNP.
    Knebel F; Schimke I; Diaz Ramirez I; Schattke S; Eddicks S; Borges AC; Baumann G
    Int J Cardiol; 2009 May; 134(2):260-3. PubMed ID: 18384896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention.
    Kwon TG; Bae JH; Jeong MH; Kim YJ; Hur SH; Seong IW; Cho MC; Seung KB; Jang YS; Park SJ;
    Int J Cardiol; 2009 Apr; 133(2):173-8. PubMed ID: 18281115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
    De Hert SG; Lorsomradee S; Cromheecke S; Van der Linden PJ
    Anesth Analg; 2007 Apr; 104(4):766-73. PubMed ID: 17377079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NT-ProBNP reduction percentage during hospital stay predicts long-term mortality and readmission in heart failure patients.
    Verdiani V; Ognibene A; Rutili MS; Lombardo C; Bacci F; Terreni A; Nozzoli C
    J Cardiovasc Med (Hagerstown); 2008 Jul; 9(7):694-9. PubMed ID: 18545069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
    Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
    Bergh CH; Andersson B; Dahlström U; Forfang K; Kivikko M; Sarapohja T; Ullman B; Wikström G
    Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative treatment with levosimendan in candidates for mechanical circulatory support.
    Sponga S; Ivanitskaia E; Potapov E; Krabatsch T; Hetzer R; Lehmkuhl H
    ASAIO J; 2012; 58(1):6-11. PubMed ID: 22157071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left ventricular remodelling in patients with moderate systolic dysfunction after myocardial infarction: favourable effects of exercise training and predictive role of N-terminal pro-brain natriuretic peptide.
    Giallauria F; Cirillo P; Lucci R; Pacileo M; De Lorenzo A; D'Agostino M; Moschella S; Psaroudaki M; Del Forno D; Orio F; Vitale DF; Chiariello M; Vigorito C
    Eur J Cardiovasc Prev Rehabil; 2008 Feb; 15(1):113-8. PubMed ID: 18277196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.